Exenatide Tracker App
Track Byetta (Twice-Daily) and Bydureon (Weekly) in Shotlee
Exenatide is the active ingredient in both Byetta (5/10 mcg twice daily, approved 2005) and Bydureon (2 mg once weekly, approved 2012). Based on exendin-4 from Gila monster venom, exenatide was the first GLP-1 receptor agonist ever approved — founding the class that now includes semaglutide, tirzepatide, and retatrutide. Track either formulation in Shotlee.
25,000+
GLP-1 Users Tracking
4.8★
App Rating
Free
Always Free
What Is Exenatide?
Exenatide is a synthetic analogue of exendin-4, a peptide originally discovered in the venom of the Gila monster lizard. With 53% sequence homology to human GLP-1 and natural resistance to DPP-4 degradation, exenatide was the compound that proved the GLP-1 receptor agonist class concept could work clinically. The FDA approved Byetta (twice-daily exenatide) on April 28, 2005 — the founding date of the modern GLP-1 drug class.
Exenatide is available in two formulations with very different dosing profiles. Byetta (5/10 mcg BID) requires meal-timed twice-daily injections and has a 2.4-hour half-life. Bydureon (2 mg weekly) uses PLGA microsphere depot technology to release exenatide slowly over 7 days. Both target the same GLP-1 receptor via the same mechanism, but Bydureon achieves more consistent plasma levels and better tolerability than Byetta.
The GLP-1 Class Founder
Without exenatide/Byetta proving the GLP-1 concept in 2005, the development timeline for semaglutide, tirzepatide, and retatrutide would likely have been significantly delayed. Every GLP-1 medication today traces its clinical rationale back to exenatide trials.
Exenatide Formulations and Doses
5 mcg BID
Byetta — Months 1–2
Starting dose for twice-daily exenatide. Inject within 60 min before breakfast and dinner. At least 6 hours between doses.
10 mcg BID
Byetta — Month 3+ (maintenance)
Maintenance dose for Byetta. Twice-daily meal-timed injection. Most clinical trial efficacy data uses this dose.
2 mg weekly
Bydureon — Fixed dose, no escalation
Single fixed dose for once-weekly extended-release exenatide. No titration required. DURATION-1: -1.6% HbA1c at 30 weeks.
Exenatide Clinical Data
HbA1c (Bydureon, DURATION-1)
-1.6%
Mean HbA1c reduction with exenatide ER 2 mg weekly at 30 weeks vs twice-daily exenatide in DURATION-1.
HbA1c (Byetta, pivotal trials)
-0.8%
Mean HbA1c reduction with exenatide 10 mcg BID vs placebo in pivotal Phase 3 trials as add-on therapy.
FDA approval year
2005
Byetta approved April 2005 — the first GLP-1 receptor agonist in clinical use, 20+ years of safety data.
What to Track in Shotlee
Whether you use Byetta twice daily or Bydureon weekly, Shotlee supports both dosing schedules with equal precision.
Injection Logs (Both Formulations)
Record each dose with time, site, and dose amount. Byetta requires 2 entries per day; Bydureon requires 1 per week.
Meal Timing (Byetta Only)
Log injection time and meal time for each Byetta dose. Consistent 30–60 minute pre-meal timing is critical for efficacy.
HbA1c & Fasting Glucose
Enter lab HbA1c from each clinic visit. Bydureon takes 6–7 weeks to steady state; assess HbA1c at 3 months.
Weekly Body Weight
Both formulations produce modest weight loss. Track weekly to quantify your personal response and trends over time.
GI Side Effects
Nausea is more common with Byetta (meal-timing dependent) than Bydureon (gradual release). Log severity and timing.
Injection Site Reactions
Bydureon microsphere nodules are common and expected. Track site, size, and resolution to guide rotation strategy.
Protocol FAQs
Both contain exenatide. Byetta (5/10 mcg twice daily) requires meal-timed injections with a 2.4-hour half-life. Bydureon (2 mg once weekly) uses microsphere depot technology for slow 7-day release. Bydureon achieves more consistent levels, less nausea, and slightly better HbA1c reduction vs Byetta.
Semaglutide (Ozempic weekly) outperforms both exenatide formulations on HbA1c reduction (1.4–1.9% vs 0.8–1.6%) and weight loss (3–6 kg vs 2–4 kg), and has demonstrated cardiovascular mortality benefit (SELECT trial). Exenatide remains relevant where cost or formulary access favours it.
In the 1990s, researcher John Eng discovered exendin-4 in Gila monster venom — a peptide with significant GLP-1 receptor activity and DPP-4 resistance. Its natural resistance to degradation was what made a practical GLP-1 drug possible. This discovery ultimately led to the entire modern GLP-1 drug class.
Yes, particularly for cost-sensitive prescribing, patients with established stable control, and markets with limited semaglutide access. The EXSCEL trial confirmed Bydureon is CV-safe (non-inferior). For patients needing maximum HbA1c or weight reduction, semaglutide or tirzepatide are preferred.
Start a new medication entry in Shotlee for Bydureon when you switch. Your Byetta history remains in the app as a reference. Note that Bydureon takes 6–7 weeks to reach steady state — your HbA1c response should be assessed at the 3-month mark after switching.
References
- [1]Clinical TrialDrucker DJ, et al. "Exenatide once weekly versus twice daily for the treatment of type 2 diabetes (DURATION-1)." Lancet. 2008;372(9645):1240-1250.
- [2]Clinical TrialHolman RR, et al. "Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL)." NEJM. 2017;377(13):1228-1239.
Track Your Exenatide Protocol in Shotlee
Log Byetta or Bydureon doses, HbA1c, weight, and side effects — all free in Shotlee.
🚀 Use Shotlee for Free